- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ESMO Congress: Researchers Identify Barriers to Drug Access
The researchers identified discrepancies across the globe in patient access to life-saving cures for cancer.
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, 2 new studies show at the ESMO 2014 Congress in Madrid, Spain.
Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.
Coordinated action is needed at an international level to ensure new cancer-fighting drugs are approved in a timely manner, oncologists said at the Congress. Their call came after a survey revealed that patients in some regions sometimes wait years longer than their counterparts elsewhere for new drugs to be approved.
MD, MSEd, FRCPC
The drug approval process is important to ensure that safe and effective therapies are made available for patients, explains study senior author Sunil Verma , from Sunnybrook Odette Cancer Center, Toronto, Canada.
To try and understand disparities in the drug approval time among various countries, Dr Verma and coauthor Nardin Samuel compared approval times for 41 cancer drugs in Canada, the US and the European Union.
Link to ESMO's press release: http://bit.ly/1v8EJ74
Discussion on global barriers to drug access at ASCO 2014: http://bit.ly/1vloEcl
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
